However, the phase Ib TATTON trial, which evaluated the safety and tolerability of combining durvalumab and osimertinib in EGFR-mutant NSCLC patients who progressed after previous EGFR-TKI, demonstrated that 38% of the patients developed serious interstitial lung disease, and the combination was deemed unfeasible [102]. The gene discussed is EGFR; the disease is interstitial lung disease.